The present study assessed the influence of urinary flow rate and urine pH on the renal excretion of the NMDA-receptor antagonist memantine. Methods In a randomized, open, four-period cross-over trial, 12 healthy male volunteers received 10 mg memantine daily for 43 days. After reaching steady state conditions the volunteers were allocated to four different regimens to alter urine pH and urinary flow, which were each separated by a 1 week period while the study medication continued (A: acidification of urine pH, low urinary flow; B: acidification of urine pH, high urinary flow; C: alkalinization of urine pH, low urinary flow; D: alkalinization of urine pH, high urinary flow). Results The renal clearance of memantine (CL R ) in regimen A and B was 7-10 fold higher in comparison with regimen C and D ( P<0.05). There were small but statistically significant differences of CL R between the two regimens with acidic urine pH (A: median: 210.2 ml min Conclusions The present study demonstrated a considerable effect of urine pH, whereas no clinically relevant change of the renal excretion of memantine with urinary flow could be detected. As the renal excretion of memantine may have an impact on therapeutic efficacy changes of dietary habits that may alter urine pH should be avoided during treatment with memantine.
Therefore, the aim of this study was to evaluate the Introduction influences of urine pH and urinary flow on the elimination of memantine. As patients usually receive a long-term Memantine (1-amino-3,5-dimethyladamantane; Akatinol Memantine), a derivate of amantadine (1-aminotreatment with memantine, influences of urine pH and urinary flow on memantine kinetics were assessed under adamantane) is used in Europe mainly in the treatment of dementia [1] [2] [3] .
multiple dose conditions. The analysis of the safety data of several controlled clinical studies indicates a plasma concentration dependence and Methods time dependence of neurological adverse effects such as confusion, agitation, insomnia, dizziness, headaches and Subjects akathisia [4] . Hence, physiological factors which influence the plasma concentration of memantine should be evaluated.
Twelve healthy male volunteers (age, range: 22-31 years; Memantine is a weak base with a pKa of 10.27 and it is body weight, range 61-95 kg) gave their written informed predominantly excreted unchanged via the kidneys [5] .
consent to participate in the study. Their health status was Urine pH has been shown to be a major determinant checked by medical history, physical examination, blood for the excretion of alkaline drugs like memantine, other chemistry, urine analysis, and ECG. The study protocol was examples are, e.g. flecainide ( pKa=9. 3) [6] or methoxyapproved by the Ethics Committee of the Medical Faculty phenamine ( pKa=10.45) [7] . Another determinant for of the University of Göttingen. renally excreted drugs is urine flow. Thus, gross changes of urine pH and/or urinary flow may lead to either toxic Study design effects or ineffective treatment.
The study refers to an open, controlled, randomized and design with multiple dosing in 12 male healthy volunteers into 1 ml n-hexane for 30 min. The organic layer was then transferred into a reaction vial containing 15 ml N-methylaccording to Good Clinical Practice (GCP). The subjects received daily medication of one tablet containing 10 mg bis-trifluoro acetamide. The sample volume was finally reduced to 150 ml at 70°C. Typically, 3 ml of sample were memantine hydrochloride (8.37 mg memantine free base, Akatinol Memantine) at 08.00 h for 43 days. Starting on injected in splitless mode into the GC apparatus. The injection port was kept at 250°C. The separation was day 21 under steady state conditions, urine pH and urinary flow of the subjects were altered according to the following carried out on a HP1 methyl silicone fused silica capillary (25 m, 0.2 mm i.d.) with helium as the carrier gas. The regimens:
A:-acidified urine pH ( pH 5) with reduced urinary column temperature was increased from 50°C to 250°C over 6.75 min in three steps. The interface to the mass flow (50 ml h −1 )
B:-acidified urine pH ( pH 5) with increased urinary selective detector was kept at 280°C. The TFA (trifluoroacetic acid)-derivatives of memantine (275±2 amu) flow (175 ml h −1 )
C:-alkalinized urine pH ( pH 8) with reduced urinary and amantadine (247±2 amu) as the internal standard were monitored. flow (50 ml h −1 ) D:-alkalinized urine pH ( pH 8) with increased urinary Calibration samples were prepared from drug free plasma and urine, respectively. The concentration signal relationship flow (175 ml h −1 )
The sequences of the regimens were randomly allocated was linear in the range from 8.4 to 267 ng ml −1 for plasma and 0.08-16 mg ml −1 for urine. The interassay variability to the subjects and were separated by a 1 week period of continued regular intake of memantine. To alkalinize the was below 2.5% for the plasma samples and below 1.5% for urine samples. urine the volunteers received doses of 4 g sodium bicarbonate (food grade, Merck, Germany). The alkalinising treatment was started at 14.00 h on the prestudy day and lasted until Pharmacokinetic analysis 22.00 h on the study day. Doses were administered in 4 h intervals. At every time of intake the volunteers received Primary investigational parameters were renal clearance water, a total volume of 600 ml during regimen C (reduced (CL R ) and total plasma clearance (CL T ) of memantine as urinary flow) and a total volume of 6000 ml during regimen well as the amount of memantine excreted into urine within D (increased urinary flow).
each regimen A-D (Ae 0-24 h ). For the computation of the To acidify the urine the volunteers received doses of 1 g individual values of CL R and CL T a compartmental ammonium chloride (food grade, Merck, Germany) every pharmacokinetic model (first-order absorption) was 3 h until 23.00 h on the study day starting at 14.00 h on developed using the pharmacokinetic modelling program the prestudy day. At every time of intake the volunteers NONMEM [8] . Pharmacokinetic modelling was employed received water, a total volume of 600 ml during regimen A because under steady state conditions and with non-constant (reduced urinary flow) and a total volume of 6000 ml during clearance, standard pharmacokinetic formulae are not valid. regimen B (increased urinary flow).
The clearances were estimated taking into account the The volunteers entered the research unit at 14.00 h on individual plasma and urine concentrations of memantine the prestudy day and remained there until 20.00 h on the and the variables urine pH and urinary flow. Calculations following study day. At 08.00 h on the study day they took were done for regimens A, B, C and D and for unchanged the study medication (10 mg memantine). Blood samples conditions of urine pH and urinary flow (U) using the for plasma concentration measurements of memantine were plasma concentrations obtained on study day 1, 10 and 15. drawn before intake of the medication and 2, 4, 6, 8, 10, Extra-renal clearance was assumed to be independent of 12, 14 and 24 h thereafter. Additional trough levels were urine pH and urinary flow. Figure 1 shows the pharmacotaken on day 1, 10 and 15 for control of steady state kinetic model. The following differential equation was used conditions and for calculation of memantine excretion under to calculate the rate constants for renal (k R ) and extra-renal conditions of unchanged urine pH and urinary flow (U).
(k XR ) excretion, where k R can be described as a function Urine collection periods for measurement of memantine of urine pH and urinary flow [k R =F (urine pH, urinary concentrations were 0-2 h, 2-4 h, 4-6 h, 6-8 h, 8-10 h, flow)]. C is memantine plasma concentration, t is time, k A 10-12 h, 12-14 h, 14-24 h. Volume and pH of the urine is the rate constant for absorption and A is dose fraction of samples were recorded and three aliquots were taken. Plasma memantine resorbed divided by central volume of distriand urine samples were stored at −20°C until analysis.
bution. CL R and CL XR are the product of the volume of distribution with k R and k XR , respectively. CL T is the sum of both clearances.
Analytical methods
Memantine in plasma and urine samples was determined dC dt =k A *A−K XR *C−k R *C with a validated assay method which employed gas chromatography with mass selective detection (Güntner, Merz+Co., unpublished) and was conducted according Secondary parameters were peak concentration (C max ), time to reach peak concentration (t max ), taken from the original Good Laboratory Practice (GLP). In brief, 0.5 ml plasma or urine was treated at 70°C for 30 min after addition of data and the area under the memantine plasma concentration time curve of each regimen from A-D (AUC(0,24h)). AUC 0.5 ml hydrochloric acid (2n). After cooling, the mixture was made alkaline by addition of 0.25 ml sodium hydroxide was calculated using the linear trapezoidal rule. Plots of DU/Dt (amount excreted during one sampling solution (32% w/v). Subsequently the analytes were extracted B: median: 26.6 ng ml −1 , 25% quartile: 22.9 ng ml −1 , 75% between the regimens with an acidic urine pH (A vs B) and between the regimens with an alkaline urine pH (C vs D) Statistical analysis was slightly different (Table 2) . Under the condition of unchanged urine pH and urinary A descriptive statistical analysis of the primary investigational parameters CL T , CL R and Ae 0-24 h as well as the secondary flow, CL R reached #75% of CL R in regimens with acidic urine conditions. In the regimens with an acidic urine pH parameters AUC(0,24h), C max , C max /AUC(0,24h) and t max of the different regimens A, B, C and D was done by (A, B) the percentage of CL R of CL T is #90%, similar to the proportion under conditions of unchanged urine pH calculating median, 25% quartile and 75% quartile.
The data are expressed as median, 25% quartile and 75% and urinary flow (U). In the regimens with an alkaline urine pH (C, D) only 50% of total clearance are due to CL R quartile. Further statistical analysis were done using the Friedman repeated measures anova (analysis of variance) on ( Table 2) . The difference of CL R between regimens with high (A, C) and low urinary flow (B, D) is # 9 ml min −1 ranks for comparisons of multiple groups. Post-tests for comparisons between single groups were carried out using regardless of acidic or alkaline urine conditions. Under acidic urine conditions this is 4% of renal clearance but under the Wilcoxon's signed rank test with a-adjustment according Bonferroni-Holm. P<0.05 was considered statistialkaline conditions this same difference amounts to 30-45%. In Figure 3 the total amount of memantine excreted into cally significant. the urine is shown for regimens A-D. The differences of Ae 0-24 h between the regimens with an acidic urine pH (A, Results B) and alkaline urine pH (C, D) are statistically significant ( P<0.05). The Ae 0-24 h was 5.7-7.4 fold higher in the Raw data regimens with an acidic urine pH A and B in comparison to the regimens with an alkaline urine pH C and D. The achieved urinary flow rates and urine pH of the regimens A-D are shown in Table 1 .
Differences between the regimens with an acidic urine pH A vs B and between the regimens with an alkaline urine Steady state concentrations were effectively reached after 21 days, as proven by memantine trough plasma levels on pH C vs D were not found to be statistically significant. days 1, 10 and 15 after start of the medication (data not shown).
Secondary parameters In Figure 2 the plasma concentration-time curves of memantine under the different treatment regimens are
The pharmacokinetic parameters C max and t max , as well as AUC(0,24h) and C max /AUC(0,24h) for each regimen are shown. Trough levels of memantine during all regimens were similar (regimen A: median: 27.0 ng ml −1 , 25% shown in Table 3 .
For C max no statistically significant differences between quartile: 22.2 ng ml −1 , 75% quartile: 30.6 ng ml −1 ; regimen Table 2 Total (CL T ) , extra-renal (CL XR ) and renal clearance (CL R ) of memantine during the respective regimens (A-D) and under conditions of unchanged urinary flow and urine pH (U). Extra-renal clearance was assumed to be independent of urine pH and urinary flow therefore estimated values are identical for the respective regimens (median=M, 25% quartile=25%, 75% quartile=75%). Regimen A: acidic urine pH, low urinary flow; B: acidic urine pH, high urinary flow; C: alkaline urine pH, low urinary flow; D: alkaline urine pH, high urinary flow. U=conditions of unchanged urine pH and urinary flow. For statistical comparisons see results section. the regimens were observed. The statistical analysis of t max , Discussion AUC(0,24h) and C max /AUC(0,24h) resulted in significant differences ( P<0.05) between the regimens with an acidic High concentrations of memantine in plasma are correlated with a higher probability of side-effects as shown in several urine pH (A, B) and the regimens with an alkaline urine pH (C, D), whereas no differences within the regimens clinical trials [4] . As the plasma concentration is dependent on elimination it is necessary to evaluate possible influences with acidic urine conditions and alkaline urine conditions could be observed.
Renal clearance in CL
of the elimination kinetics of memantine which is predominantly excreted via the kidneys. Major determinants for Plots of DU/Dt (amount excreted during one sampling period) vs plasma concentration at the midpoint of the renal elimination of alkaline drugs are urine pH and urinary flow [5, 6] . Therefore, we investigated the excretion of the sampling period could be fitted by linear regression, no dependence of renal clearance on memantine plasma weak base memantine ( pKa=10.27) under conditions of alkaline ( pH 8) and acidic ( pH 5) urine pH and high and concentration was seen (Figure 4) . low urinary flow rates, respectively. This range of urinary pH can be found under physiological conditions [9] . For the calculation of renal, extra-renal and total clearance of memantine under these conditions, the pharmacokinetic modelling program NONMEM [8] was used. By computation with a one-compartmental model, estimation of extra-renal and total clearance of memantine under a multiple dosing regime without detection of metabolites and memantine excreted within the faeces was possible.
The results of the study show that plasma concentrations of memantine are dependent on urine pH. Alkaline urine pH results in a reduced renal excretion and renal clearance in comparison with acidic urine pH. The reduced renal clearance at alkaline urine pH can be explained by pH-dependent tubular reabsorption under these conditions because the ratio of nonionized memantine in alkaline solutions ( pH 8) is considerably higher (0.005) than in acidic urine ( pH 5), where the ratio of nonionized drug is very low (0.000005). Under these conditions tubular reabsorption seems to be unlikely, in contrast tubular secretion must be taken into account, as the renal clearance of memantine at acidic pH exceeds the expected glomerular filtration rate.
Urinary flow rates are no major determinants of memantine pharmacokinetics. A high urinary flow rate results in an increase of renal clearance of about 9 ml min with first order kinetics.
be described by linear regression in accordance with first order kinetics.
Taken together, the pharmacokinetics of memantine are recommendations for memantine. Naunyn Schmiedeberg's Arch considerably affected by urine pH at high and low 
